DK3348556T3 - Heteroarylamider som hæmmere af proteinaggregering - Google Patents

Heteroarylamider som hæmmere af proteinaggregering Download PDF

Info

Publication number
DK3348556T3
DK3348556T3 DK18156929.4T DK18156929T DK3348556T3 DK 3348556 T3 DK3348556 T3 DK 3348556T3 DK 18156929 T DK18156929 T DK 18156929T DK 3348556 T3 DK3348556 T3 DK 3348556T3
Authority
DK
Denmark
Prior art keywords
heteroarylamides
inhibitors
protein aggregation
aggregation
protein
Prior art date
Application number
DK18156929.4T
Other languages
Danish (da)
English (en)
Inventor
Emily M Stocking
Wolfgang Wrasidlo
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3348556(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Application granted granted Critical
Publication of DK3348556T3 publication Critical patent/DK3348556T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK18156929.4T 2014-01-29 2015-01-28 Heteroarylamider som hæmmere af proteinaggregering DK3348556T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
EP15705417.2A EP3099684B8 (en) 2014-01-29 2015-01-28 Heteroaryl amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
DK3348556T3 true DK3348556T3 (da) 2020-08-03

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18156929.4T DK3348556T3 (da) 2014-01-29 2015-01-28 Heteroarylamider som hæmmere af proteinaggregering
DK15705417.2T DK3099684T3 (en) 2014-01-29 2015-01-28 HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15705417.2T DK3099684T3 (en) 2014-01-29 2015-01-28 HETEROARYLAMIDS AS INHIBITORS OF PROTEIN AGGREGATION

Country Status (38)

Country Link
US (3) US9738635B2 (enExample)
EP (2) EP3099684B8 (enExample)
JP (2) JP6619741B2 (enExample)
KR (1) KR102383038B1 (enExample)
CN (2) CN111039939B (enExample)
AP (1) AP2016009347A0 (enExample)
AU (1) AU2015211119B2 (enExample)
BR (2) BR112016017344B1 (enExample)
CA (1) CA2937967C (enExample)
CL (1) CL2016001918A1 (enExample)
CR (1) CR20160394A (enExample)
CY (2) CY1120348T1 (enExample)
DK (2) DK3348556T3 (enExample)
EA (1) EA032374B1 (enExample)
EC (1) ECSP16070327A (enExample)
ES (2) ES2808978T3 (enExample)
HK (1) HK1231470A1 (enExample)
HR (2) HRP20180813T1 (enExample)
HU (2) HUE050964T2 (enExample)
IL (1) IL246987B (enExample)
LT (2) LT3348556T (enExample)
ME (1) ME03800B (enExample)
MX (1) MX2016009896A (enExample)
MY (1) MY187450A (enExample)
NZ (1) NZ722487A (enExample)
PE (1) PE20161393A1 (enExample)
PH (1) PH12016501493A1 (enExample)
PL (2) PL3348556T3 (enExample)
PT (2) PT3099684T (enExample)
RS (2) RS57533B1 (enExample)
SA (1) SA516371579B1 (enExample)
SG (1) SG11201606108RA (enExample)
SI (2) SI3099684T1 (enExample)
SM (2) SMT202000376T1 (enExample)
TR (1) TR201809440T4 (enExample)
UA (1) UA118209C2 (enExample)
WO (1) WO2015116663A1 (enExample)
ZA (1) ZA201605246B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20160394A (es) 2014-01-29 2016-11-01 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregación de proteína
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
ES2882285T3 (es) * 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
MX2019007054A (es) 2017-01-26 2019-08-29 Ucb Biopharma Sprl Derivados de alcoxi bis-heteroarilo como moduladores de la agregacion de proteinas.
CA3062749A1 (en) * 2017-05-12 2018-11-15 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Compounds for use in the treatment or prevention of melanoma
JP2020529432A (ja) * 2017-08-04 2020-10-08 アキシャル バイオセラピューティクス, インク.Axial Biotherapeutics, Inc. 微生物により誘発されるアミロイドの阻害剤
AU2018360514A1 (en) * 2017-10-31 2020-05-14 Loma Linda University Methods for treating traumatic brain injury
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
CN118488951A (zh) * 2021-12-27 2024-08-13 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
JP2025541967A (ja) * 2022-11-02 2025-12-24 エーシー・イミューン・エス・アー Ｔｄｐ－４３タンパク質症の診断のための新規化合物
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
WO2004048343A1 (en) * 2002-11-28 2004-06-10 Schering Aktiengesellschaft Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
CN100536837C (zh) * 2003-02-27 2009-09-09 乔安妮·麦克劳林 鲨肌醇在制备诊断试剂中的用途
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
EP1697371B1 (en) * 2003-12-19 2007-04-25 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
BR122020017756B1 (pt) * 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
AU2005287692B2 (en) * 2004-09-20 2012-07-12 4Sc Ag Novel heterocyclic NF-kappaB inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
BRPI0615524A2 (pt) 2005-07-11 2010-04-06 Devgen Nv derivados da amida como inibidores da quinase
EA016300B1 (ru) * 2005-07-29 2012-04-30 4ЭсЦэ АГ НОВЫЕ ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ NF-κB
BRPI0709595A2 (pt) * 2006-03-15 2011-07-19 4Sc Ag inibidores de nf-kapab heterocìclicos
US8362066B2 (en) * 2006-11-17 2013-01-29 Treventis Corporation Compounds and methods for treating protein folding disorders
US8450481B2 (en) * 2007-06-14 2013-05-28 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
US8598356B2 (en) * 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
EP2491026A1 (en) 2009-10-20 2012-08-29 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
BR112012014807A2 (pt) * 2009-12-16 2017-06-27 Neuropore Therapies Inc "compostos adequados para o tratamento de sinucleopatias"
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
EP2830608B8 (en) 2012-03-28 2020-01-15 UCB Biopharma SRL Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
MX2015000618A (es) 2012-07-16 2015-04-10 Neuropore Therapies Inc Derivados de di- y tri-heteroarilo como inhibidores de la agregacion de proteinas.
CR20160394A (es) 2014-01-29 2016-11-01 Neuropore Therapies Inc Heteroaril amidas como inhibidores de agregación de proteína
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
EA201991755A1 (ru) 2017-01-26 2020-01-22 Юсб Байофарма Спрл Бициклические бисгетероарильные производные в качестве модуляторов агрегации белков
ES2882285T3 (es) 2017-01-26 2021-12-01 Ucb Biopharma Sprl Derivados de bis-heteroarilo como moduladores de la agregación de proteínas

Also Published As

Publication number Publication date
PT3099684T (pt) 2018-10-22
US10358443B2 (en) 2019-07-23
US9738635B2 (en) 2017-08-22
MY187450A (en) 2021-09-22
PT3348556T (pt) 2020-07-27
SA516371579B1 (ar) 2019-07-16
HUE050964T2 (hu) 2021-01-28
AP2016009347A0 (en) 2016-07-31
MX2016009896A (es) 2017-01-11
LT3348556T (lt) 2020-08-10
RS57533B1 (sr) 2018-10-31
ES2808978T8 (es) 2021-03-22
CR20160394A (es) 2016-11-01
SI3348556T1 (sl) 2020-10-30
US20160207912A1 (en) 2016-07-21
PH12016501493B1 (en) 2017-02-06
KR20160113287A (ko) 2016-09-28
US11078196B2 (en) 2021-08-03
ES2675301T3 (es) 2018-07-10
IL246987B (en) 2021-12-01
DK3099684T3 (en) 2018-07-16
JP2019163321A (ja) 2019-09-26
WO2015116663A8 (en) 2016-09-15
SMT202000376T1 (it) 2020-09-10
AU2015211119B2 (en) 2019-05-30
JP6619741B2 (ja) 2019-12-11
IL246987A0 (en) 2016-09-29
EA032374B1 (ru) 2019-05-31
EP3348556B1 (en) 2020-04-29
HRP20201107T8 (hr) 2020-12-11
JP2017505779A (ja) 2017-02-23
US20180093979A1 (en) 2018-04-05
KR102383038B1 (ko) 2022-04-05
CL2016001918A1 (es) 2017-01-13
PL3348556T3 (pl) 2020-11-02
BR112016017344B1 (pt) 2023-05-16
NZ722487A (en) 2022-04-29
HRP20180813T1 (hr) 2018-07-27
JP6783900B2 (ja) 2020-11-11
EA201691529A1 (ru) 2017-01-30
CA2937967C (en) 2022-07-26
RS60547B1 (sr) 2020-08-31
SG11201606108RA (en) 2016-08-30
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06
CN106132960B (zh) 2019-12-17
BR112016017344A2 (pt) 2017-10-03
BR122018001892B1 (pt) 2023-05-02
LT3099684T (lt) 2018-06-25
EP3099684B8 (en) 2018-07-04
SMT201800318T1 (it) 2018-07-17
AU2015211119A8 (en) 2016-12-15
CY1120348T1 (el) 2019-07-10
PE20161393A1 (es) 2017-01-08
SI3099684T1 (en) 2018-08-31
TR201809440T4 (tr) 2018-07-23
HK1231470A1 (zh) 2017-12-22
PH12016501493A1 (en) 2017-02-06
EP3099684B1 (en) 2018-04-04
CA2937967A1 (en) 2015-08-06
ES2808978T3 (es) 2021-03-02
EP3099684A1 (en) 2016-12-07
ZA201605246B (en) 2022-05-25
ME03800B (me) 2021-04-20
CN111039939A (zh) 2020-04-21
CN111039939B (zh) 2023-09-19
AU2015211119A1 (en) 2016-08-11
US20190308965A1 (en) 2019-10-10
PL3099684T3 (pl) 2018-09-28
ECSP16070327A (es) 2018-05-31
CN106132960A (zh) 2016-11-16
CY1123374T1 (el) 2021-12-31
HRP20201107T1 (hr) 2020-10-30
HUE040274T2 (hu) 2019-03-28
EP3348556A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
DK3348556T3 (da) Heteroarylamider som hæmmere af proteinaggregering
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3164380T3 (da) Hæmmere af lysinspecifik demethylase-1
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3160956T3 (da) Inhibitorer af lysin-specifik demethylase-1
DK3160994T3 (da) Multispecifikke antigenbindende proteiner
DK3116475T3 (da) Dopa-decarboxylasehæmmersammensætninger
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
EP3494971C0 (en) ERK INHIBITOR SALTS
DK3186241T3 (da) Prober til billeddannelse af huntington-protein
DK3094322T3 (da) Administration af tasimelteon i fastende tilstand
DK3099791T3 (da) Protein
DK3418273T3 (da) Derivater af flavagliner
DK3204352T3 (da) Hæmmere af lysin-gingipain
DK3143123T3 (da) Mikrorna-induktion af kardiologisk regenerering
HRP20181570T1 (hr) Režim doziranja spoja fgf-18
DK3137658T3 (da) Anvendelse af kendte forbindelser som d-aminosyreoxidase-inhibitorer
HRP20182029T1 (hr) Uti-fuzijski proteini
EP3137649C0 (en) METALLIZATION OF SURFACES